immunotherapy agents were required in 90%; eight patients required IVIG and rituximab. Steroid weaning commonly precipitated relapses. Four patients had complete remission, the remaining patients still require immunotherapy. Necrotising Autoimmune Myopathy is a potentially treatable myopathy, which can be precipitated by statin therapy and requires early, aggressive immunotherapy, usually requiring multiple steroid sparing agents for successful steroid weaning.
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Introduction:
Necrotising Autoimmune Myopathy (NAM), otherwise known as immune-mediated necrotising myopathy (IMNM), is an increasingly recognised condition that presents as a subacute symmetrical proximal myopathy accompanied by high creatine kinase (CK) levels [1] [2] [3] [4] . It can be associated with myalgia, dysphagia, dyspnoea, fatigue and weight loss [1, 5] .
It has been linked to statin medication exposure, 3-hydroxy-3-methylglutaryl-CoA reductase antibody (anti-HMGCR) [6] [7] [8] , connective tissue diseases, signal recognition particle antibody (anti-SRP) [9] , malignancy and viral infections including the Human Immunodeficiency Virus (HIV) [1, 2] .
Muscle biopsy findings in NAM generally show necrotic and regenerating fibres with minimal inflammatory infiltrate, and no evidence of vasculitis [10, 11] .
There is still limited data on treatment options, with no prospective trials, but some case series have explored various immunosuppressive agents, with NAM symptoms generally being less receptive to immunotherapy than the inflammatory myopathies and requiring at least a 12-month trial of high dose prednisolone, usually with at least one steroid sparing agent [5, 9, 12] . A recent case series by Kassardjian et al [5] , exploring the clinical response of 63 patients to various immunomodulating therapies across the subtypes of NAM, showed that >50% of patients relapse during the taper of immunotherapy, and the majority of patients needed two or more immunosuppressive agents.
This study aims to add to the current literature with our Western Australian NAM patient cohort, documenting the clinical, biochemical, serological and biopsy findings along with the treatment and subsequent outcomes.
Methods:
We identified patients that had presented to the Western Australian Neuroscience Research Institute (WANRI) between the years 2000 to 2015 and received the diagnosis of NAM by the treating neuromuscular specialist Neurologist and Immunologist. Other causes of a necrotising myopathy, such as hypothyroidism, muscular dystrophy and other toxic myopathies were routinely excluded.
We retrospectively collected data on presentation, investigation, treatment and clinical course. All patients underwent serial CK levels and muscle power examinations, which were recorded using the Medical Research Council scale and used as a measure of patient response. These were performed at each clinic visit, which was initially monthly, then every three months during treatment for the majority of patients. Serological results were recorded, including myositis autoantibodies, anti-SRP and anti-HMGCR antibodies. These were performed using the Euroimmun Myositis Immunoblot and the PathWest HMGCR ELISA [13] . All muscle biopsies were sent to the Neuropathology Department of PathWest at Royal Perth Hospital and reviewed by a neuropathologist. All biopsies underwent the same standard muscle biopsy protocol, including: H&E, modified Gomori trichrome, PAS and PASD, Oil 
Results:
We identified 20 patients with NAM: 14 with anti-HMGCR antibodies (70%), two with anti-SRP antibodies (10%), three associated with connective tissue disease (15%), and two as yet unspecified. Patient age at presentation varied from 28 -78 years (mean 58.3); 12 patients (60%) were women. All 20 presented with history of proximal weakness; almost one third had dysphagia; six complained of myalgia (30%). Four patients had symptoms of dyspnoea, with pulmonary function tests consistent with respiratory muscle weakness in three patients, while the remaining patient had evidence of pulmonary fibrosis on imaging. The majority of patients had a symmetrical proximal limb-girdle weakness, with only four patients presenting with a pattern of more severe lower limb weakness than upper limb weakness (see Table 1 ).
Neck flexor weakness was found in five patients (25%), while seven patients exhibited some weakness affecting movements of the elbows or knees. Only one patient, with connective tissue disease associated NAM, was found to have distal weakness. The tempo of symptom evolution prior to presentation ranged from two weeks to 6 months, with the median duration of symptoms at presentation being four months. One patient, from the statin associated antiPage 4 of 20 HMGCR group, presented with a more chronic history of myalgia and generalised subjective weakness over a period of three years, and had no objective weakness on examination.
Muscle biopsy was performed in 19 cases, processed at a single centre, and reviewed by a specialised neuropathologist. All biopsies had regenerating fibres; necrotic fibres were seen in seventeen cases, these were single fibres and polyphasic. Major Histocompatibility Of the remaining 12 patients, all with previous stain exposure, eleven had muscle biopsies performed, all showing either necrotic or regenerating fibres. Two patients did not have necrotic fibres seen on biopsy, but these biopsies were performed after immunosuppression had already been commenced. Myonecrosis was mostly mild, with moderate numbers of regenerating fibres. Three biopsies also showed a mild perivascular inflammatory cell infiltrate and another, mild endomysial inflammation. Eight biopsies were mildly positive for MHC-I, with one of these also positive for MAC with mild patchy sarcolemmal staining.
None of the biopsies stained positive for MHC-II.
One patient was managed conservatively without immunosuppression and one patient was only recently diagnosed and had not yet commenced immunotherapy. All other patients required high dose prednisolone weaned over at least 12 months; five patients required only one steroid-sparing agent (three had methotrexate, one mycophenolate, and one azathioprine).
Three patients required regular intravenous immunoglobulin (IVIG) therapy (either fortnightly or monthly) and of those three, two received rituximab therapy due to difficulty weaning off the prednisolone or relapses. Three patients in total received rituximab. Of this subgroup, only four patients achieved a complete clinical and biochemical remission and no longer required therapy, with courses of immunotherapy ranging from 12 to 120 months (see 
3.2Anti-SRP Antibody positive
Only two patients were found to be positive for the anti-SRP antibody. Initial CK levels were 5762 and 10 000U/L and initial MRC power grade of 3 and 3-respectively. Both patient biopsies showed mild necrosis and regenerating fibres, and no inflammation. Patient B also had moderate diffuse MHC-I positivity.
Patient A is still experiencing ongoing symptoms, despite an immunotherapy regime that has included prednisolone, methotrexate, azathioprine, IVIG, rituximab and tacrolimus over a 14 year period. This particular patient responded very well to rituximab initially but then relapsed with prednisolone weaning (see Figure 2. 3).
Patient B initially received prednisolone, methotrexate and IVIG, which induced a clinical recovery of power to baseline, but the patient continues to have persistently elevated CK over the 3.5 years of prednisolone and methotrexate tapering.
Connective Tissue Disease Associated
Three patients were found to have NAM associated with connective tissue disease, 
Discussion:
We present a retrospective cohort of 20 Australian patients with Necrotising Autoimmune Myopathy, detailing our experience in diagnosing and treating this heterogeneous disease with comparisons across the aetiological subgroups: anti-HMGCR positive, anti-SRP positive and connective tissue disease associated.
All patients were initially referred to our clinic with a symmetrical proximal muscle weakness and a significantly elevated CK level, in keeping with the presentation findings of previous studies [1] [2] [3] [4] [5] 10, 12, 14] . In our anecdotal experience, these patients also often have muscle atrophy at presentation, in comparison to the other inflammatory myopathy patients, where this is not commonly seen. In agreement with the 119 th ENMC International
Workshop on idiopathic inflammatory myopathies [15] , none of our patients exhibited extraocular or neck extensor weakness. The majority of patients had equally weak upper and lower limb girdles, with only four patients exhibiting isolated weakness of the pelvic girdle. Five patients also had weakness of neck flexion on examination. Consistent with other recent studies, almost one third of our cohort had dysphagia and 30% complained of myalgia [1, 5, 16] , with the majority of these patients being anti-HMGCR antibody positive with statin exposure (see Table 1 ). Creatine kinase levels were very high across the series (average 6858U/L), with the highest levels found in the anti-HMGCR positive group.
Respiratory muscle weakness was not routinely investigated, nor was cardiac dysfunction, although both have been reported in the literature, particularly in association with anti-SRP (1,5,17).
Our study classified patients into subtypes according to serology and associated conditions.
In all except two patients, we were able to identify potential precipitants to the development of NAM, the most common being statin exposure with positive anti-HMGCR antibodies (n=12, 60%). As expected, this group tended to be older than their statin-naïve counterparts, with on average less severe weakness. The anti-HMGCR positive patients without previous statin exposure were much younger with very high average CK levels of 10000 and more severe weakness (see Table 1 ). One of these patients was of African descent, the other Caucasian. Both these patients required Rituximab and IVIG therapy to gain symptomatic improvement and are both requiring ongoing immunotherapy. This correlates with the findings of Mohassel et al [8] : that statin-naïve patients with positive anti-HMGCR antibodies are more resistant to therapy, and furthers the hypothesis that these patients could represent a clinically distinct subgroup of NAM. Both the anti-SRP positive and connective tissue disease related patients were also comparatively young, with the anti-SRP patients having similarly high CK levels and weakness severity. In contrast, the connective-tissue disease associated patients had relatively preserved power and lower CK levels. These Treatment of NAM is notoriously difficult, with most cases being refractory to conventional immunotherapy with a high relapse rate when steroid weaning is attempted [1, 4, 5, 7, 8, 12, 14] .
Our study results again confirm this, with only four patients able to discontinue immunotherapy and achieve complete remission, all from the statin exposed anti-HMGCR positive subgroup, with one patient requiring ten years of slowly weaning methotrexate and prednisolone. Of our cohort, 80% of patients (n = 16) are still requiring immunotherapy, with 40% of these still experiencing some residual weakness, although improved from initial presentation. The average duration of immunotherapy is 40 months thus far, with the majority of patients requiring two or more steroid sparing agents in addition to prednisolone, and 45%
requiring three or more agents. As shown in the individual case graphs (see charts 1-5), NAM is clinically and biochemically responsive to steroids and liable to relapse with steroid weaning. Recent studies have focused on the role of IVIG and Rituximab in treating refractory NAM patients [20, 21] . In our experience, IVIG plays an important role in enabling steroid tapering and improving clinical function, and is useful for treating acute and severe relapses. Of the eight patients who required IVIG and/or Rituximab therapy (see Table 1 ), three of the patients receiving IVIG achieved complete resolution of symptoms, but all are still requiring some additional form of immunotherapy. Rituximab use enabled prednisolone weaning and cessation of IVIG in two patients.
Conclusion:
Necrotising Autoimmune Myopathy is a potentially treatable immune-mediated myopathy, which needs to be differentiated from other causes of myocyte necrosis, such as hypothyroidism, muscular dystrophies and other toxic myopathies. It clinically presents with a subacute proximal limb girdle weakness that develops over weeks to months. Biopsy 
